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Abstract
Background: Fluralaner is the first orally administered isoxazoline to provide 12 weeks of activity against fleas and
ticks after a single administration. As a result of its potent anti-flea activity, oral fluralaner may be proposed as a
component of a strategy for the control of flea allergy dermatitis (FAD) in dogs. The open field study reported here
assessed the efficacy of fluralaner for long-term control (up to 6 months) of FAD in affected client-owned dogs
maintained under common household conditions in the Ile-de-France region.
Methods: This was an open pre-treatment versus post-treatment study. Client-owned dogs with clinical signs
of FAD were recruited and treated with oral fluralaner (Bravecto®) at 25-56 mg/kg body weight on days 0 and 84.
The dogs’ condition was assessed at each visit (on days 0, 28, 84 and 168) using the following three parameters:
(i) extent of skin lesions based on the scoring system for canine FAD; (ii) pruritus severity based on the pruritus
visual analog scale; (iii) presence or absence of fleas or flea feces.
Results: Of the 26 dogs initially enrolled, 23 were presented on day 28, 20 on day 84 and 16 for the final evaluation on
day 168. Eighteen out of 20 dogs (90 %) presented on day 84 and 15 out of 16 dogs (94 %) presented on day 168
showed a complete clinical resolution. The post-treatment FAD clinical scores on days 28, 84 and 168 were significantly
different from that of the pre-treatment with a reduction of 89.8 %, 98.8 % and 99.8 %, respectively. The post-treatment
pruritus index values on days 28, 84 and 168 were significantly different from that of the pre-treatment with a
reduction of 45.2 %, 71.2 % and 80.8 %, respectively.
Conclusions: The present study confirmed that oral fluralaner treatment should be considered as effective for long-
term control of clinical signs in FAD affected dogs.
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Background
Ctenocephalides felis is the main flea species infesting
both dogs and cats. It also represents the most important
ectoparasite for dogs in many parts of the world. Without
treatment, a persistent flea infestation can induce intense
pruritus and self-inflicted trauma. With repeated ex-
posure, dogs may develop hypersensitivity to compo-
nents of flea saliva, a “condition” that leads to flea
allergy dermatitis (FAD) [1, 2]. Dogs that are predisposed
to FAD and live in a flea endemic area will typically de-
velop clinical signs by the age of 5 years. However, clinical
signs can develop at any age, particularly if animals move
from a low-exposure risk area to an area where fleas are
endemic. Once sensitization has occurred, clinical relapse
can be initiated by a small number of flea bites [3].
In dogs, the typical clinical presentation of FAD is a
pruritic papular dermatitis that is concentrated on the
rump, dorsal thorax, flanks, tail, and perineal area.
Pruritus is usually focused on the caudal areas and tail,
although some dogs express generalized pruritus. Clinical
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signs can include alopecia, crusts, hyperpigmentation,
lichenification and pyotraumatic dermatitis lesions. Sec-
ondary skin infections frequently complicate the clinical
picture of dogs, which can develop bacterial folliculitis
and/or Malassezia dermatitis [1–3].
The isoxazolines are a novel class of antiparasitic
drugs that inhibit gamma-aminobutyric acid (GABA)
and glutamate-gated chloride channels with significant
selectivity for insect neuron receptors compared with
mammalian receptors. This results in excess neuronal
stimulation and arthropod death. To date, this new class
includes three molecules: afoxolaner, fluralaner, sarolaner,
which are all formulated for prescription by veterinarians
as flavored chewable tablets for dogs. Fluralaner is the first
orally administered active ingredient (Bravecto®, MSD
Animal Health, Madison NJ) to provide 12 weeks of in-
secticidal activity against fleas and up to 12 weeks of
acaricidal activity against important tick genera after a
single administration. Following oral administration to
dogs, fluralaner is rapidly absorbed and provides 100 %
effectiveness against fleas and ticks within 12 h. Blood
levels are then sustained and provide a high level of flea
and tick killing activity for up to 12 weeks [4, 5]. Oral
fluralaner has shown efficacy as a component of a strat-
egy for control of FAD [6–8]. A polymer matrix collar
containing a combination of 10 % imidacloprid and
4.5 % flumethrin has been licensed for use in dogs and
cats and this collar confers a long-term (8 months) pro-
tection against fleas (and ticks).
The open field study reported here assessed the efficacy
of fluralaner for long-term control (up to 6 months)
of FAD in affected client-owned dogs maintained
under common household conditions in the Ile-de-
France region.
Methods
This was an open pre-treatment versus post-treatment
clinical field study. The study was conducted in the
Small Animal Hospital of Alfort Veterinary College
(CHUVA, France) from June 2014 to July 2015. Cases
were recruited from the canine patient population
presented for examination at the dermatology unit of
the hospital.
Client-owned dogs diagnosed with FAD were enrolled
in the study with written informed consent from their
owners. All dogs came from Ile-de-France region and
were each enrolled independently. During the study,
dogs were kept at home by their owners and fed and
exercised according to their usual routine.
Dogs were diagnosed with FAD on the basis of clinical
signs consistent with published descriptions [9, 10]
and exhibited both pruritus and typical FAD lesions
were noticed. Lesions compatible with FAD included:
erythema, papules, alopecia, crusts, lichenification and
hyperpigmentation in specific areas (dorsolumbar, ano-
genital, tail), and/or pyotraumatic dermatitis.
Dogs were excluded from the study if: (i) they had
been treated with an external antiparasitic treatment
within the 30 days before presentation; (ii) they were
suspected to have sarcoptic mange or showed a positive
otopodal reflex; (iii) they were suspected to have canine
atopic dermatitis (CAD). CAD diagnosis was based on
the following clinical criteria [9]: facial lesions, otitis,
pododermatitis or carpal or tarsal dermatitis. The ab-
sence of flea or flea feces was not included in exclusion
criteria. Dogs were not included if it was not possible to
treat all animals in the household against fleas.
During the first visit (day 0), the clinical history was
collected for each dog and a standard clinical examin-
ation was performed. The owner was requested to
present each enrolled dog for clinical evaluation on days
0, 28 (D0 + 1 month), 84 (D0 + 3 months) and 168
(D0 + 6 months). The dog’s condition was assessed at
each visit using the following three parameters:
1. Skin lesions were measured by a veterinary
dermatologist using the scoring system for canine
FAD (SSCFAD, based on Laffort-Dassot et al. [9]).
This scoring system is based on evaluation of 6
primary and secondary lesions (erythema, papules,
excoriations, alopecia, kerato-seborrheic dermatitis
and lichenification) at each of 6 body areas
(dorsolumbar area, lateral area, hind limb, ano-
genital area, front-ventral area and hind ventral area).
Each lesion is graded from 0 (no clinical sign) to 10
(severe signs). The minimum possible score is 0, and
the maximum possible score (indicating the most
severe skin lesions) is 360.
2. Pruritus severity was assessed by the dog owner
using a validated pruritus visual analog scale (PVAS)
[11] using a score from 0 to 10.
3. Presence or absence of fleas or flea feces. Fleas were
counted if they were observed.
Each dog was treated with a Bravecto® tablet admin-
istered according to the SPC recommended dose
based on the dog’s weight on day 0 and again on day
84 (D0 + 3 months). Included dogs received no concomi-
tant treatment with any other flea-control drugs or with
any drug with antipruritic or anti-inflammatory activity
throughout the 6-month study. Antiseptic or antibiotic
treatments were allowed only during the first month of
the study. Cohabiting animals residing at study house-
holds also received an antiparasitic treatment either with
indoxacarb spot-on (Activyl®) for cats (every month), or
oral fluralaner (Bravecto®) for dogs (every 12 weeks).
Owners were asked to report any observed health issues
or adverse events following treatment. An antiparasitic
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spray/fogger could be used for the house, at the discretion
of the veterinarian.
The SSCFAD reduction was calculated at each time
point t using the SSCFAD arithmetic mean in the fol-
lowing formula:
SSCFAD reduction %ð Þ
¼ 100  mean day 0 – mean tð Þ=mean day 0:
The PVAS reduction was calculated at each time point
t using the arithmetic mean of pruritus scale according
to the following formula:
PVAS reduction %ð Þ
¼ 100  mean day 0 – mean tð Þ=mean day 0:
SSCFAD and PVAS values were analyzed by a mixed
linear model including day as a fixed effect. Kenward-
Roger correction was used to determine the denomin-
ator degrees of freedom [12]. Least squares means were
used for treatment comparisons.
The null hypothesis was that there was no significant
difference in the testing parameter between the pre-
treatment and post-treatment. Two tailed tests were used
for the comparison. Statistical significance was declared
when P ≤ 0.05. The primary software was SAS version 9.3
(SAS Institute Inc., Cary, NC, USA).
Results
Twenty-six client-owned dogs with suspected FAD were
enrolled in the study. They were mixed and pure breed,
ranging from 1 to 14 years old, and weighing between
4.5 and 40 kg. There were 11 females and 15 males. Four
breeds were more frequently represented: Maltese (4),
Jack Russell Terrier (4), Labrador Retriever (3) and
Shih Tzu (3). Fourteen dogs lived in a house with ac-
cess to a garden while 12 exclusively lived in an
apartment. Fourteen of the enrolled dogs were the
only animal of the house, while 12 lived with at least
one other pet (Additional file 1).
Five of the 26 enrolled dogs received a topical antisep-
tic treatment during the first month, and nine received
antibiotics (sometimes combined with topical antiseptic
treatments). A spray formulation (containing permethrin
and (S)-methopren) (Tiquanis®) was used for the control
of environmental stages of fleas in five cases. Of the 26
dogs enrolled on day 0, 23 were presented on day 28, 20 on
day 84 and 16 for the final clinical evaluation, on day 168.
Clinical examination on the first visit found that dogs
mostly showed lesions in two body areas: the dorso-
lumbar area and the ano-genital area. Eighteen out of 20
dogs (90 %) presented on day 84 and 15 out of 16 dogs
(94 %) presented on day 168 showed complete clinical
resolution. A significant improvement in clinical signs
was observed for all the dogs over the study period
(Table 1 and Fig. 1). The post-treatment FAD clinical
scores on days 28, 84 and 168 were significantly different
from that of the pre-treatment on day 0 (P values <
0.0001 for all 3 post-treatment days) with a reduction of
89.8 %, 98.8 % and 99.8 %, respectively. The FAD clinical
scores on post-treatment days 28, 84 and 168 were not
significantly different (P = 0.3651 for the difference be-
tween day 28 and day 84; P = 0.3511 for the difference
between day 28 and day 168; P = 0.9363 for the differ-
ence between day 84 and day 168) from each other.
The owner assessment of pruritus decreased signifi-
cantly over the same period (Table 1). The post-treatment
pruritus visual analogue scales on post-treatment days 28,
84 and 168 were significantly different from that of the
pre-treatment (P values < 0.0001 for all 3 post-treatment
days) (Additional file 2), with a reduction of 45.2 %,
71.2 %, and 80.8 %, respectively. The PVAS values on
post-treatment days 84 and 168 were significantly different
from that on the post-treatment day 28 (P = 0.0031 for the
difference between day 28 and day 84; P = 0.0002 for the
difference between day 28 and day 168), but were not sig-
nificantly different from each other (P = 0.2963). The
SSCFAD reduction and the pruritus score reduction were
not affected by whether the dog had access to a garden or
lived with another pet in the household (data not shown).
The flea count mean was 1.38 on day 0; this decreased to
0.00 on day 28 and remained at 0.00 on days 84 and 168.
An antiparasitic spray was used in the house (on day 0)
in only five of the cases (17 %). Due to this small number,
it was not possible to show any difference in response
when comparing houses that were fogged and those that
were not fogged.
No adverse clinical event was observed in any dog
after either of the two oral fluralaner administrations at
days 0 and 84.
Discussion
This is the first report to show long-term successful
management of FAD, as enrolled dogs were requested to
return for follow-up examinations at a final visit 168 days
(6 months) following the first treatment. This report was
an open study because both investigators and owners
knew which treatment was being administered to the
dogs. An untreated control group was not included for
Table 1 Clinical scores assessed by a veterinary dermatologist
and pruritus severity assessed by owners in FAD-affected dogs
following oral fluralaner treatment
Parameter D0 D28 D84 D168
Number of dogs 26 23 20 16
Mean SSCFAD-score values 54 5.5 0.6 0.1
Mean pruritus scale values 7.3 4 2.1 1.4
P value compared with D0 < 0.0001 < 0.0001 < 0.0001
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ethical reasons. To date, there are only few clinical field
studies published regarding treatment strategies for con-
trolling FAD in dogs [7, 8, 13]. Rohdich et al. [7] con-
ducted a randomized, multi-centered field European
study to compare the flea- and tick-control efficacy for
dogs over a 12-week period with either a single oral dose
of fluralaner or with three sequential topical fipronil
treatments. Of dogs showing clinical FAD at the study
start, 85.7 % (30 out of 35) in the fluralaner-treated
group and 55.6 % (10 out of 18) in the fipronil-treated
group were evaluated at each time point as showing no
clinical signs of FAD until study completion. Fisara et al.
[13] evaluated the clinical response to topical indoxacarb
treatment every 4 weeks for 12 weeks in 25 client-owned
dogs with FAD in Australia [12]. Of the 24 dogs that
completed the study, 21 (87.5 %) showed complete reso-
lution of clinical signs on the final visit. Fisara et al. [8]
conducted an open study to assess the clinical response
in 20 FAD affected dogs in Australia over a 12-week
period following a single oral fluralaner treatment [8].
All clinical signs of FAD in dogs included in this study
had resolved at the final assessment. In the two last
studies, the assessment of dogs with FAD was based on
canine atopic dermatitis extent and severity index ver-
sion 3 (CADESI-03) [8, 13]. The CADESI-03 scale is val-
idated to score canine atopic disease skin lesions and is
recommended for use in clinical trials of atopic dogs,
but not for FAD. In the present study, a specific scoring
system (SSCFAD) was used to assess the progression of
clinical signs over the course of the trial. However, this
scoring system, based on Laffort-Dassot et al. [9], has
not been tested for validity, reliability (i.e. inter- and
intra-observer reliability and internal consistency), and
responsiveness (i.e. sensitivity to change). In the present
study, 18 of the 20 dogs (90 %) presented on day 84 and
15 of the 16 dogs (94 %) presented on day 168 showed
complete clinical resolution.
Assessment of the severity of pruritus in dogs is crit-
ical and difficult. Various methods have been described
but, to date, only one has been validated: the Pruritus
Visual Analog Scale (PVAS) [11]. This scale was used
in two out of three previous studies about FAD in
dogs [8, 13]. In the present study PVAS was confirmed to
be an easy and repeatable method for owners.
FAD was diagnosed in affected dogs on the basis of
observed compatible skin lesions at typical body loca-
tions, and by exclusion of other primary pruritic skin
diseases. Dogs were not skin tested with flea allergens.
Some authors [8, 10, 13] used intradermal injection of
flea antigens or serology as diagnostic criteria for FAD.
However, positive immediate intradermal flea antigen re-
activity can be observed in normal dogs, and Kunkle et
al. [14] reported that 24 % of dogs can show a false-
positive reaction to flea extract injections. Laffort et al.
[9] demonstrated that skin testing with pure flea saliva
provided the best correlation between the clinical ap-
proach to FAD diagnosis and intradermal testing, with a
sensitivity of 93 %, a specificity of 90 %, and an overall
accuracy of 91 % [9].
Several different insecticides (and combinations) are
known to be effective against fleas and can be used to
control the clinical signs of FAD. In order to deliver the
best possible control of flea allergy, the antiparasitic
drug should combine two major characteristics: (i) a
quick flea adulticide activity; and (ii) a long duration of
action with persistent efficacy. Fluralaner meets both cri-
teria and is currently the only isoxazoline to deliver flea
insecticidal efficacy >95 % for 12 weeks [4, 5]. In the
present study there was no increase of mean SSCFAD or
PVAS scores at D84 or D168 suggesting that a long-
term control of fleas is an effective way to manage the
clinical signs of FAD in dogs.
Conclusions
Two oral fluralaner treatments effectively controlled the
clinical signs of FAD in dogs and reduced the severity of
the pruritus as assessed by the dog owner over a
6 months period. Orally administered fluralaner is effect-
ive for long-term control of FAD.
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Fig. 1 A 6 year-old Jack Russell Terrier presented with a dorsolumbar
lesion at day 0 (a) and the same dog at day 84 (b) showing complete
resolution of the lesion
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